

Robin E Ferner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8985502/publications.pdf>

Version: 2024-02-01

76
papers

1,983
citations

331670
21
h-index

265206
42
g-index

85
all docs

85
docs citations

85
times ranked

2785
citing authors

#	ARTICLE	IF	CITATIONS
1	Free-of-charge medicine schemes in the NHS: A local and regional drug and therapeutic committee's experience. British Journal of Clinical Pharmacology, 2022, 88, 2571-2580.	2.4	1
2	Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity. Drug Safety, 2022, 45, 137-144.	3.2	15
3	Phenytoin and damage to the cerebellum – a systematic review of published cases. Expert Opinion on Drug Safety, 2022, 21, 957-977.	2.4	4
4	Deaths attributed to the use of medications purchased online. BMJ Evidence-Based Medicine, 2022, 27, 60-64.	3.5	18
5	Overprescribing and rational therapeutics: Barriers to change and opportunities to improve. British Journal of Clinical Pharmacology, 2021, 87, 34-38.	2.4	8
6	Tramadol: repeated prescriptions and repeated warnings. BMJ Evidence-Based Medicine, 2021, 26, e17-e17.	3.5	9
7	Coping with COVID: preparing prescribers during the pandemic. British Journal of Clinical Pharmacology, 2021, , .	2.4	1
8	Medical Devices: Classification and Analysis of Faults Leading to Harms. Drug Safety, 2020, 43, 95-102.	3.2	2
9	A novel approach to support implementation of biosimilars within a UK tertiary hospital. British Journal of Clinical Pharmacology, 2020, 86, 23-28.	2.4	7
10	Medical Devices: Definition, Classification, and Regulatory Implications. Drug Safety, 2020, 43, 83-93.	3.2	47
11	Are high-cost drug funding mechanisms fit for purpose? A retrospective study of individual funding requests in an NHS tertiary hospital. British Journal of Clinical Pharmacology, 2020, , .	2.4	2
12	Chloroquine and hydroxychloroquine in covid-19. BMJ, The, 2020, 369, m1432.	6.0	297
13	Remdesivir in covid-19. BMJ, The, 2020, 369, m1610.	6.0	91
14	Establishing a service to tackle problematic polypharmacy. Future Healthcare Journal, 2020, 7, 208-211.	1.4	6
15	Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50. British Journal of Clinical Pharmacology, 2019, 85, 2218-2227.	2.4	7
16	Susceptibility to adverse drug reactions. British Journal of Clinical Pharmacology, 2019, 85, 2205-2212.	2.4	24
17	Antithrombotic dose: Some observations from published clinical trials. British Journal of Clinical Pharmacology, 2019, 85, 2194-2197.	2.4	1
18	The relationship between antemortem and postmortem morphine concentrations. Clinical Toxicology, 2019, 57, 1142-1145.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Preventing Future Deaths from Medicines: Responses to Coronersâ€™ Concerns in England and Wales. Drug Safety, 2019, 42, 445-451.	3.2	19
20	The toxicological significance of post-mortem drug concentrations in bile. Clinical Toxicology, 2018, 56, 7-14.	1.9	17
21	Deaths from Medicines: A Systematic Analysis of Coronersâ€™ Reports to Prevent Future Deaths. Drug Safety, 2018, 41, 103-110.	3.2	42
22	Adverse drug reactions. BMJ: British Medical Journal, 2018, 363, k4051.	2.3	14
23	Prescribing biosimilars. BMJ: British Medical Journal, 2018, 362, k3141.	2.3	10
24	Twenty years of adverse drug reactions: a look back â€“ part 1. Adverse Drug Reaction Bulletin, 2018, 309, 1195-1198.	0.5	0
25	Twenty years of adverse drug reactions: a look back â€“ part 2. Adverse Drug Reaction Bulletin, 2018, 310, 1199-1202.	0.5	0
26	A systematic review of the evidence for acute tolerance to alcohol â€“ the â€œMellanby effectâ€. Clinical Toxicology, 2017, 55, 545-556.	1.9	34
27	Unlicensed and offâ€label uses of medicines: definitions and clarification of terminology. British Journal of Clinical Pharmacology, 2017, 83, 2615-2625.	2.4	55
28	Perceptions and Impact of Mandatory eLearning for Foundation Trainee Doctors: A Qualitative Evaluation. PLoS ONE, 2016, 11, e0168558.	2.5	11
29	Manslaughter trials ignore systemic failures. BMJ, The, 2016, 355, i6630.	6.0	0
30	How similar are biosimilars?. BMJ, The, 2016, 353, i2721.	6.0	11
31	The law of mass action and the pharmacological concentrationâ€effect curve: resolving the paradox of apparently nonâ€doseâ€related adverse drug reactions. British Journal of Clinical Pharmacology, 2016, 81, 56-61.	2.4	19
32	Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology. British Journal of Clinical Pharmacology, 2016, 81, 52-55.	2.4	21
33	Nominal ISOMERs (Incorrect Spellings Of Medicines Eluding Researchers)â€variants in the spellings of drug names in PubMed: a database review. BMJ, The, 2016, 355, i4854.	6.0	6
34	Mefloquine for malarial prophylaxis in military personnel. BMJ, The, 2015, 351, h5797.	6.0	5
35	Authorsâ€™ reply to Green and colleagues. BMJ, The, 2015, 351, h6588.	6.0	0
36	A systematic review and metaâ€analysis of thiazideâ€induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?. British Journal of Clinical Pharmacology, 2015, 79, 566-577.	2.4	52

#	ARTICLE	IF	CITATIONS
37	Temporal and other factors that influence the time doctors take to prescribe using an electronic prescribing system. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 206-212.	4.4	10
38	Harms from medicines: inevitable, in error or intentional. British Journal of Clinical Pharmacology, 2014, 77, 403-409.	2.4	8
39	A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy. Journal of the Royal Society of Medicine, 2013, 106, 87-119.	2.0	14
40	Raising more antibodies. BMJ, The, 2013, 347, f5969-f5969.	6.0	2
41	Medical manslaughter. BMJ, The, 2013, 347, f5609-f5609.	6.0	10
42	Piquancy. BMJ, The, 2013, 346, f2938-f2938.	6.0	0
43	A fat chance of slimming. BMJ, The, 2013, 347, f7389-f7389.	6.0	0
44	Hallucination. BMJ, The, 2013, 347, f4570-f4570.	6.0	0
45	A bee in the bonnet about honey and healing. BMJ, The, 2013, 347, f5015-f5015.	6.0	0
46	Divination. BMJ, The, 2013, 346, f1536-f1536.	6.0	0
47	Beneath the surface. BMJ, The, 2013, 346, f380-f380.	6.0	0
48	A short history of pharmaceutical marketing. BMJ, The, 2012, 345, e7801-e7801.	6.0	0
49	Susceptibilities. BMJ, The, 2012, 345, e6420-e6420.	6.0	1
50	Dose Omissions in Hospitalized Patients in a UK Hospital. Drug Safety, 2012, 35, 677-683.	3.2	22
51	Internet Accounts of Serious Adverse Drug Reactions. Drug Safety, 2012, 35, 1159-1170.	3.2	37
52	Deriving Dose Limits for Warnings in Electronic Prescribing Systems. Drug Safety, 2012, 35, 291-298.	3.2	7
53	Interactions. BMJ: British Medical Journal, 2012, 344, e865-e865.	2.3	0
54	Consequences. BMJ, The, 2012, 344, e2859-e2859.	6.0	0

#	ARTICLE	IF	CITATIONS
55	Summertime. BMJ, The, 2012, 344, e4245-e4245.	6.0	0
56	Boundaries. BMJ: British Medical Journal, 2012, 344, e2028-e2028.	2.3	0
57	An agenda for UK clinical pharmacology: Medication errors. British Journal of Clinical Pharmacology, 2012, 73, 912-916.	2.4	12
58	Patient Experiences of Serious Adverse Drug Reactions and Their Attitudes to Medicines. Drug Safety, 2011, 34, 319-328.	3.2	52
59	Biochemical Monitoring of Patients Treated with Antihypertensive Therapy for Adverse Drug Reactions. Drug Safety, 2011, 34, 1049-1059.	3.2	10
60	Can an electronic prescribing system detect doctors who are more likely to make a serious prescribing error?. Journal of the Royal Society of Medicine, 2011, 104, 208-218.	2.0	19
61	Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care. British Journal of Clinical Pharmacology, 2010, 70, 109-117.	2.4	15
62	Preventability of Drug-Related Harms â€” Part I. Drug Safety, 2010, 33, 985-994.	3.2	61
63	Preventability of Drug-Related Harms â€” Part II. Drug Safety, 2010, 33, 995-1002.	3.2	34
64	An Algorithm for Integrating Contraindications into Electronic Prescribing Decision Support. Drug Safety, 2010, 33, 1089-1096.	3.2	10
65	EIDOS. Drug Safety, 2010, 33, 15-23.	3.2	35
66	The problem of orphan drugs. BMJ: British Medical Journal, 2010, 341, c6456-c6456.	2.3	22
67	Medication errors: problems and recommendations from a consensus meeting. British Journal of Clinical Pharmacology, 2009, 67, 592-598.	2.4	47
68	The pathophysiology of medication errors: how and where they arise. British Journal of Clinical Pharmacology, 2009, 67, 605-613.	2.4	99
69	The epidemiology of medication errors: the methodological difficulties. British Journal of Clinical Pharmacology, 2009, 67, 614-620.	2.4	51
70	A Strategy for Regulatory Action When New Adverse Effects of a Licensed Product Emerge. Drug Safety, 2009, 32, 91-98.	3.2	17
71	Ethnic Differences in the Risks of Adverse Reactions to Drugs Used in the Treatment of Psychoses and Depression. Drug Safety, 2008, 31, 597-607.	3.2	35
72	Over the counter medicines: proceed with caution. BMJ: British Medical Journal, 2008, 336, 694-696.	2.3	22

#	ARTICLE	IF	CITATIONS
73	Clarification of Terminology in Medication Errors. Drug Safety, 2006, 29, 1011-1022.	3.2	207
74	Clarification of Terminology in Drug Safety. Drug Safety, 2005, 28, 851-870.	3.2	221
75	Monitoring drug treatment. BMJ: British Medical Journal, 2003, 327, 1179-1181.	2.3	27
76	Prescribing direct-acting oral anticoagulants â€“ Mind the evidence gap. British Journal of Clinical Pharmacology, 0, , .	2.4	1